KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBITDA Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBITDA Margin for 15 consecutive years, with 1.86% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 1415.0% to 1.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.66% through Dec 2025, down 2100.0% year-over-year, with the annual reading at 8.66% for FY2025, 2100.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 1.86% at Supernus Pharmaceuticals, up from 31.35% in the prior quarter.
  • The five-year high for EBITDA Margin was 24.14% in Q2 2021, with the low at 31.35% in Q3 2025.
  • Average EBITDA Margin over 5 years is 4.84%, with a median of 4.56% recorded in 2021.
  • The sharpest move saw EBITDA Margin skyrocketed 2638bps in 2024, then crashed -5460bps in 2025.
  • Over 5 years, EBITDA Margin stood at 3.83% in 2021, then soared by 435bps to 20.52% in 2022, then tumbled by -103bps to 0.61% in 2023, then soared by 2128bps to 12.29% in 2024, then tumbled by -115bps to 1.86% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 1.86%, 31.35%, and 7.34% for Q4 2025, Q3 2025, and Q2 2025 respectively.